<SEC-DOCUMENT>0001576885-23-000013.txt : 20230327
<SEC-HEADER>0001576885-23-000013.hdr.sgml : 20230327
<ACCEPTANCE-DATETIME>20230327074222
ACCESSION NUMBER:		0001576885-23-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20230327
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230327
DATE AS OF CHANGE:		20230327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acumen Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001576885
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				364108129
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40551
		FILM NUMBER:		23761452

	BUSINESS ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		925-368-8508

	MAIL ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abos-20230327.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:6730fab0-04e2-4506-98f0-957d32cfd7bd,g:65d29e65-6349-4329-a4c2-11a15f4c79cc,d:a94cea34cb5941da85ff18b920806e25--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abos-20230327</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i114d26b02d9240199568a1385ed93dba_D20230327-20230327" name="dei:EntityCentralIndexKey" id="f-22">0001576885</ix:nonNumeric><ix:nonNumeric contextRef="i114d26b02d9240199568a1385ed93dba_D20230327-20230327" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abos-20230327.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i114d26b02d9240199568a1385ed93dba_D20230327-20230327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576885</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia94cea34cb5941da85ff18b920806e25_1"></div><div style="min-height:45pt;width:100%"><div><